We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Digital Pathology Approach Helps Identify New NSCLC Biomarkers

By LabMedica International staff writers
Posted on 21 Jun 2023

Lung cancer is the leading cause of cancer-related deaths among both genders globally, with a five-year survival rate standing at a mere 18%. More...

Non-small cell lung cancer (NSCLC), divided further into adenocarcinoma, squamous cell carcinoma, and a few rarer types, is the most common diagnosis for these patients. Emerging evidence underscores the critical role of the collagen fiber-rich microenvironment surrounding cancer cells in the growth of these cancers and other solid tumors. In this tumor context, high type I collagen expression is linked to poor prognosis and higher metastasis risk. This association suggests that fibrillar collagens could serve as a key source of cancer-relevant biomarkers and has sparked interest in deciphering their roles in tumor development.

In response to this challenge, researchers at the University of Barcelona (Barcelona, Spain) and the Institute of Bioengineering of Catalonia (IBEC, (Barcelona, Spain) have developed and validated a novel digital pathology approach that quantitatively analyzes collagen fibers in tissue samples from NSCLC patients. The approach utilizes digitized images of patient biopsies stained with a dye named picrosirius red (PSR) and imaged with polarized light. The researchers employed the open-source software CT-FIRE to automatically segment individual fibers in the images and quantify critical characteristics like length, width, or straightness.

The team applied this methodology to analyze 195 samples from patients with adenocarcinoma and squamous cell carcinoma. The findings suggest that fiber straightness could serve as a potential disease biomarker, while high density could indicate a poor prognosis. Interestingly, the prognostic relevance of collagen density appears independent of the clinical tumor stage, suggesting that collagen fiber analysis provides additional crucial information. The new methodology also enabled the comparison of collagen fibers in patient tissue samples with non-cancerous tissue samples. This allowed, for the first time, a quantitative description of the changes occurring in collagen organization in NSCLC. The findings indicate that tumor tissue samples showed an increase in straightness, length, and width, suggestive of abnormal tissue stiffening, especially in adenocarcinoma patients. According to the researchers, this stiffening could be related to various mechanisms that help the tumor evade the immune response, thereby potentially facilitating tumor progression in this type of cancer.

“Our new tool can improve the clinical management of surgical patients with this type of cancer, since it identifies those at an increased risk of relapse and, therefore, can benefit from a comprehensive monitoring and even neoadjuvant therapies (complementary to the main treatment)”, noted Jordi Alcaraz, lecturer at the Faculty of Medicine and Health Sciences of the UB and researcher at IBEC.

Related Links:
University of Barcelona 
IBEC 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.